Developing as a significant development in the struggle against obesity, this medication is generating considerable attention . This treatment combines properties of two established GLP-1 receptor agonists, semaglutide , plus an unique glucose-dependent incretin component. Early clinical results have demonstrated substantial body reduction in peop